16 December 2020 | Statements

Unitaid welcomes contribution from Canada

Geneva – Unitaid welcomes contribution of C$15 million (US$11.7 million) from Canada to its ongoing work on COVID-19 therapeutics and diagnostics under the global Access to Covid-19 Tools (ACT) Accelerator.

The funding, which forms part of a C$255 million overall package of support to the ACT-Accelerator, has been allocated to Unitaid to support equitable access to promising COVID-19 treatments and tests.

This important contribution to the ACT-A Therapeutics Pillar will be used to expand and adapt the portfolio of fit-for-purpose monoclonal antibodies for low- and middle-income countries, and address issues of supply, affordability and uptake of care.

Canada has also announced funding of C$230 million to procure monoclonal antibodies for low- and middle-income countries. This investment from Canada will ensure that should the treatment prove effective, it will reach low-resource countries at the same time as high-income ones.

Unitaid Executive Director Philippe Duneton said: “Unitaid commends Canada for its commitment to the principle of making treatments and tests for COVID-19 available to everyone who needs them. This contribution to Unitaid will help us make those principles a reality.”

Media contact:  

Hervé Verhoosel | +44 7729 618634 | verhooselh@unitaid.who.int

View All News

Featured News

27 July 2021

Unitaid paving the way for hepatitis C elimination

Read More

26 July 2021

Innovative agreement launches affordable, optimal second-line HIV treatment in low- and middle-income countries

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.